Late Stage AMD is the Leading Cause of Blindness in Older Americans1
At Samsara Vision, our novel IMT technology combined with our patient support program provides health care providers with an important option to treat their most visually impaired patients living with Late-stage AMD. We’re also invested in creating next-generation devices and delivery systems that will improve the surgical experience for both the provider and the patient. Our goal is to help the late-stage AMD patient population gain access to technology that is proven to improve their quality of life and extend the freedom they have to reengage in the activities that are most important to them.
Market Opportunity:
A 2017 study published in JAMA Ophthalmology by Neely and colleagues revealed that a large number of AMD cases go undetected and undiagnosed in the primary eye care setting.2
As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050.3
AMD is the leading cause of irreversible visual loss in the United States, with variable degrees of age-related macular changes occurring in more than 10% of the population aged 65-74 years and 25% of the population older than 74 years.4
The number of individuals in the United States with AMD is estimated to increase more than 50% from 1.75 million in 2000 to 2.95 million in 2020.5
67
1. Age-related Macular Degeneration. National Eye Institute. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration 2. Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G, Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA Ophthalmol. 2017;135(6):570–575. doi:10.1001/jamaophthalmol.2017.0830 3. National Institutes of Health, National Eye Institute. Prevalence of Blindness** Data--Data Tables, Summary of Eye Disease Prevalence Data: “Prevalence of Cataract, Age-Related Macular Degeneration, and Open-Angle Glaucoma Among Adults 40 Years and Older in the United States” https://nei.nih.gov/eyedata/pbd_tables Archives of Ophthalmology, Volume 122, April 2004; 4. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003; 121(11):1621-4 (ISSN: 0003-9950) 5. The Eye Diseases Prevalence Research Group*. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. doi:10.1001/archopht.122.4.564 6. Age Related Macular Degeneration Data and Statistics. NEI. NIH. Last updated July 2019. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics 7. https://www.globaldata.com/more-than-half-of-all-age-related-macular-degeneration-cases-go-undiagnosed/
6
7